Gout — Pathophysiology and Management

Gout is an inflammatory arthropathy caused by monosodium urate (MSU) crystal deposition in joints and surrounding tissues, representing the most common form of inflammatory arthritis in men. The disease exists on a spectrum from asymptomatic hyperuricemia through acute inflammatory attacks to chronic tophaceous gout with permanent joint damage. With a prevalence of 1-2% in developed nations and rising incidence correlating with obesity, metabolic syndrome, and aging populations, gout represents a significant clinical burden affecting predominantly middle-aged and older men, though incidence in women increases significantly after menopause. Understanding gout pathophysiology is essential for USMLE success, as the examination emphasizes the relationship between serum uric acid levels, crystal formation, and innate immune activation. Proper management requires both acute episode treatment and long-term urate-lowering therapy (ULT) to prevent recurrent attacks and tophi formation.

Gout results from a complex interplay between uric acid biochemistry, crystal formation mechanics, and innate immune system activation:

Uric acid, the end product of purine metabolism in humans (lacking uricase enzyme unlike other mammals), is generated through catabolism of dietary purines and endogenous nucleotide breakdown. Approximately two-thirds of uric acid is renally excreted via glomerular filtration followed by reabsorption in the proximal tubule (via URAT1 transporter), with the remaining one-third cleared through intestinal secretion and bacterial degradation. Hyperuricemia (serum uric acid >6.8 mg/dL at physiologic pH and temperature) results from either overproduction (10% of cases, due to increased HGPRT deficiency, PRPP synthetase overactivity, or high purine intake) or underexcretion (90% of cases, from reduced renal clearance via URAT1 upregulation, chronic kidney disease, or genetic polymorphisms). The threshold of 6.8 mg/dL represents the saturation point above which MSU crystallization becomes thermodynamically favorable in physiologic conditions.

When serum uric acid exceeds saturation, monosodium urate (MSU) crystals precipitate preferentially in peripheral joints (first metatarsophalangeal joint most common due to lower temperature, lower pH from lactate accumulation, and lower synovial fluid proteoglycan content). Crystal nucleation is facilitated by lower temperature (explaining podagra predilection), acidic microenvironment, joint trauma, and presence of proteoglycans that serve as nucleation templates. Once deposited, needle-shaped MSU crystals are phagocytosed by resident macrophages and synovial lining cells through a clathrin-dependent mechanism, triggering NLRP3 inflammasome activation—the critical molecular event in acute gout pathogenesis.

MSU crystal uptake activates the NLRP3 (nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3) inflammasome, a multiprotein complex consisting of NLRP3, ASC, and pro-caspase-1. Crystal internalization causes phagolysosomal rupture and cathepsin B release into the cytoplasm (signal 1), while MSU crystals themselves provide the danger-associated molecular pattern (DAMP) signal. This dual signaling leads to caspase-1 activation, which cleaves pro-IL-1β and pro-IL-18 into their active secreted forms. Interleukin-1β (IL-1β), the primary driver of acute gouty inflammation, acts on IL-1 receptors on endothelial cells and synovial fibroblasts to upregulate COX-2 and prostaglandin production, adhesion molecule expression (ICAM-1, E-selectin), and chemokine secretion (IL-8, MCP-1). These mediators recruit neutrophils into the joint, which further amplify inflammation through production of additional IL-1β and reactive oxygen species, creating a self-perpetuating inflammatory cascade.

Paradoxically, acute gout attacks resolve spontaneously within 7-10 days even without treatment, despite persistent MSU crystals in the joint. Resolution involves apolipoprotein B-100 (apoB-100) coating of crystals, reducing their immunogenicity, and induction of transforming growth factor-β (TGF-β) and IL-37, which suppress further inflammasome activation. Neutrophil apoptosis and clearance by macrophages in an anti-inflammatory manner further promotes resolution. This self-limited nature explains why NSAIDs, colchicine, and corticosteroids are effective—they suppress the inflammatory response rather than directly affecting crystals.

With recurrent hyperuricemic episodes, persistent MSU crystals accumulate in soft tissues forming tophi (granulomatous deposits consisting of monocytes, fibroblasts, and giant cells surrounding MSU crystal cores). Tophi represent chronic inflammatory response with sustained TNF-α and IL-6 production, leading to local tissue destruction, bone erosions, and permanent joint damage through activation of osteoclasts via RANKL signaling.

Reduced renal uric acid clearance represents the predominant mechanism and includes: chronic kidney disease (GFR decline reduces filtration and increases reabsorption), diuretic use (thiazides and loop diuretics inhibit URAT1-mediated secretion in the proximal tubule), genetic polymorphisms in URAT1 and other renal transporters (particularly common in Asian populations), hypertension, metabolic syndrome with insulin resistance (hyperinsulinemia increases URAT1 expression), and dehydration from any cause.

Increased purine metabolism occurs with: myeloproliferative disorders and other malignancies (high cell turnover), tumor lysis syndrome (massive nucleic acid catabolism), hemolytic anemias, psoriasis (rapid keratinocyte turnover), HGPRT deficiency (Lesch-Nyhan syndrome with severe childhood gout), PRPP synthetase superactivity (X-linked, causes severe early-onset gout), and high dietary purine intake (red meat, organ meats, seafood, high-fructose corn syrup, and alcohol—particularly beer due to high purine content from yeast).

Alcohol consumption, especially beer, increases gout risk through both increased purine load and reduced renal urate excretion via lactate competition for renal tubular secretion. High-purine diet (red meat, shellfish, organ meats) directly increases uric acid production. High-fructose intake increases de novo purine synthesis through activation of PRPP synthetase. Dehydration and rapid weight loss both precipitate attacks through volume depletion and increased tubular reabsorption. Purine-rich foods including anchovies, sardines, organ meats, and game meats are classical board associations.

Diuretics (thiazides and loop diuretics) are among the most common iatrogenic causes. Aspirin at low doses (<3 g/day) increases serum urate through URAT1 reabsorption enhancement; high-dose aspirin (>3 g/day) has mild uricosuric effect. Cyclosporine and tacrolimus impair renal uric acid excretion. Levodopa and some chemotherapy agents increase uric acid production.

Chronic kidney disease (most important modifiable risk), hypertension, type 2 diabetes mellitus, metabolic syndrome, obesity, cardiovascular disease, and cancer predispose to gout through various mechanisms.

The classic presentation is sudden-onset, severe monoarticular arthritis typically occurring at night or early morning, with maximal pain intensity reached within 24-48 hours. The first metatarsophalangeal joint (podagra) is affected in 50% of initial attacks due to lower temperature and lower pH, but attacks can involve ankles, knees, wrists, and elbows. Pain is often described as the worst pain the patient has ever experienced, with patients unable to tolerate even bed sheet contact (cardinal sign). The inflammatory response is dramatic, with rapid development of erythema, edema, warmth, and occasionally skin desquamation; overlying skin may appear shiny and tense. Associated systemic symptoms may include fever, malaise, and elevated white blood cell count, sometimes prompting misdiagnosis as infection.

Severe joint swelling, erythema, and warmth are typical, with the joint appearing acutely inflamed. Limitation of motion is marked, and palpation elicits severe tenderness. In chronic gout, tophi appear as firm nodules over the helix of the ear (classic location), fingers, toes, elbows, and Achilles tendons; these may have a chalky appearance if MSU deposits have crystallized at the surface. Tophi can ulcerate and drain white, chalky material (urate crystals). Joint deformities from chronic erosive disease may develop with recurrent attacks.

Many patients have elevated serum uric acid without any symptoms or attacks; progression to symptomatic gout occurs at a rate of approximately 5% per year depending on degree of hyperuricemia.

Between acute attacks, patients are typically asymptomatic with normal or near-normal joint findings, though subclinical inflammation may persist. The interval between first and second attacks averages 1 year but varies widely (can be months to decades). Each attack typically lasts 7-10 days if untreated, though treatment can shorten duration to 24-48 hours.

While initial attacks are typically monoarticular, recurrent attacks can involve multiple joints simultaneously, particularly in patients with long-standing disease or very high uric acid levels. This presentation may resemble rheumatoid arthritis and requires differentiation by arthrocentesis.

Arthrocentesis with synovial fluid examination remains the diagnostic gold standard. Aspirated synovial fluid should be analyzed for: (1) MSU crystals identified using polarized light microscopy appearing as needle-shaped, negatively birefringent crystals (blue when parallel to compensator axis) within neutrophils (intracellular location suggests acute gout); (2) white blood cell count (typically 5,000-50,000 cells/μL in acute gout, predominantly neutrophils); (3) Gram stain and culture to exclude infectious arthritis (essential, as septic arthritis can coexist with gout). Crystal identification has approximately 90% sensitivity and 100% specificity for gout when characteristic intracellular MSU crystals are identified. Absence of crystals does not exclude gout but should prompt investigation of alternative diagnoses.

Serum uric acid should be measured, though interpretation requires clinical correlation: (1) >6.8 mg/dL indicates supersaturation and risk for crystal formation (normal varies by lab but typically <7 mg/dL); (2) during acute attacks, serum uric acid may paradoxically be lower than baseline due to acute inflammatory response and should not be used to diagnose or exclude gout; (3) measurement should be performed at least 2-4 weeks after acute attack resolution for accurate baseline assessment; (4) serum uric acid does not correlate precisely with gout severity or attack frequency.

24-hour urine uric acid excretion distinguishes underexcretors (<600 mg/day on regular diet) from overproducers (>800 mg/day), which has therapeutic implications: underexcretors benefit from uricosuric agents or xanthine oxidase inhibitors, while overproducers are preferentially treated with xanthine oxidase inhibitors or uricase. This test should be performed during normouricemic period (not during acute attack or while on ULT) on a regular purine diet. Clinical utility is limited in routine practice but valuable for refractory or frequent attacks.

Plain radiographs may show: (1) normal findings in early gout; (2) punched-out lytic lesions with overhanging edges in chronic tophaceous gout (pathognomonic finding when present); (3) joint space narrowing and degenerative changes in long-standing disease. Ultrasound demonstrates: (1) double-contour sign (echogenic line on superficial joint cartilage surface) highly specific for gout; (2) MSU crystal aggregates as hyperechoic material; (3) tophaceous deposits as heterogeneous echogenic masses. CT can identify tophi and erosions but is not routinely indicated for diagnosis. Imaging is not required for diagnosis but can confirm chronic gout or help differentiate from other arthropathies.

The 2015 ACR Gout Classification Criteria were developed using machine learning and assess probability of gout based on: (1) pattern of joint involvement (first metatarsophalangeal joint involvement is highly predictive); (2) clinical course (self-limited attacks, intercritical periods); (3) patient characteristics (male sex, age); (4) laboratory findings (serum uric acid >6 mg/dL, presence of MSU crystals in synovial fluid). These criteria yield a gout probability score; however, confirmed MSU crystal identification on synovial fluid analysis remains the diagnostic reference standard and should be pursued when diagnosis is uncertain.

Acute gout must be differentiated from: (1) septic arthritis (fever, elevated inflammatory markers, positive culture; can coexist with gout); (2) pseudogout (calcium pyrophosphate dihydrate crystals, rhomboid and positively birefringent, typically affecting knees in older patients); (3) rheumatoid arthritis (polyarticular, symmetric, morning stiffness >1 hour, positive rheumatoid factor/anti-CCP); (4) acute cellulitis or erysipelas (skin involvement without true joint effusion); (5) Lyme arthritis (epidemiologic context, oligoarthritis, positive serology). Arthrocentesis is essential when diagnosis is uncertain, particularly to exclude infection.

Treatment of acute attacks aims to rapidly suppress inflammation, not affect serum urate levels. NSAIDs are first-line for patients without contraindications: indomethacin (50 mg three times daily until attack resolves, then taper) or naproxen (500 mg twice daily) are traditional choices; alternative NSAIDs including ibuprofen are equally effective. Mechanism involves COX-1/COX-2 inhibition reducing prostaglandin-mediated inflammation. NSAIDs should be avoided in patients with: severe renal impairment (GFR <30 mL/min), advanced heart failure, recent myocardial infarction, or active peptic ulcer disease. Gastrointestinal protection with proton pump inhibitors should be considered in high-risk patients.

Colchicine is highly effective when initiated early (<36 hours from attack onset) with mechanism involving microtubule destabilization reducing neutrophil chemotaxis and NLRP3 inflammasome activation. Low-dose colchicine regimen (preferred in modern practice): 1.2 mg oral loading dose followed by 0.6 mg one hour later, then 0.6 mg once or twice daily until attack resolves (typically 3-5 days); this regimen has efficacy comparable to traditional higher doses with significantly fewer gastrointestinal side effects. Contraindications include renal impairment (reduce dose if GFR <30 mL/min) and hepatic dysfunction. Colchicine is preferred when NSAIDs are contraindicated or in patients with renal disease (dose adjustment required). Drug interactions are significant: strong CYP3A4 inhibitors (clarithromycin, ritonavir) contraind